Program
HRS-5632
A development code. Also written as “HRS-5632 Injection”.
Its studies are mostly in Dyslipidemias, led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Sep 15, 20252 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 21 open or running | phase 2since Sep 15, 2025 | Nov 12, 2024 | Apr 2027phase 2 · NCT07185776 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-5632
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2024First study: phase 1 study in DyslipidemiasFirst studyNCT06732154 · 50 enrolled · China
- Sep 15, 2025Phase 2 study in Lipoprotein DisorderNCT07185776 · 203 enrolled · China
Ahead
- Apr 2027Primary completion: phase 2 study in Lipoprotein DisorderNCT07185776
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07185776Lipoprotein Disorder · China | 2 | Active, not recruiting | Apr 2027 | 203 |
| NCT06732154Dyslipidemias · China | 1 | Completed | Mar 2, 2026 | 50 |
How it is read
Names in the registry
- “HRS-5632”, 1 entry
- “HRS-5632 Injection”, 1 entry
Codes read as this program: HRS5632.
Conditions, from the studies’ own filings
- Dyslipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.